| Code | CSB-RA011590MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to lebrikizumab, targeting interleukin-13 (IL-13), a key type 2 inflammatory cytokine. IL-13 plays a central role in allergic inflammation and tissue remodeling by promoting IgE synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. This cytokine signals through a heterodimeric receptor complex and is critically involved in the pathogenesis of atopic dermatitis, asthma, idiopathic pulmonary fibrosis, and other type 2 inflammatory diseases. Dysregulated IL-13 signaling contributes to epithelial barrier dysfunction, eosinophil recruitment, and chronic inflammatory responses.
Lebrikizumab is a high-affinity humanized IgG4 monoclonal antibody that specifically binds to IL-13 and prevents its interaction with IL-13Rα1, thereby blocking downstream signaling pathways. This biosimilar antibody serves as a valuable research tool for investigating IL-13-mediated mechanisms in inflammatory and fibrotic disorders, evaluating therapeutic targets in type 2 immunity, and studying cytokine-receptor interactions in preclinical models. It enables researchers to explore the therapeutic potential of IL-13 inhibition across various disease contexts.
There are currently no reviews for this product.